Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
June 7, 2022
Targeting protein degradation 3 – from discovery to the clinic (TPD3)
Area of Focus
Oncology
Targeted Protein Degradation
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
